Inflammation, malnutrition and vascular contraction in experimental chronic kidney disease

Journal of Nephrology

Volumn 20, Issue 4, 2007, Pages 423-429

  Brymora, Andrzej ^a   Flisiński, Mariusz ^a   Grześk, Grzegorz ^a   Szadujkis Szadurski, Leszek ^a   Odrowaz Sypniewska, Grazyna ^a   Manitius, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Chronic kidney disease; Inflammation; Vascular contraction

Indexed keywords

ALBUMIN; ALPHA 1 ADRENERGIC RECEPTOR; CREATININE; HAPTOGLOBIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ARTERY TONE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BLOOD VESSEL REACTIVITY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; INFLAMMATION; KIDNEY FAILURE; MALE; MALNUTRITION; NEPHRECTOMY; NONHUMAN; PERFUSION PRESSURE; RAT; SMOOTH MUSCLE CONTRACTILITY; UREA NITROGEN BLOOD LEVEL; VASOCONSTRICTION; WISTAR RAT;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; ARTERIES; ARTERIOSCLEROSIS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; HAPTOGLOBINS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MALNUTRITION; MUSCLE CONTRACTION; MYOCYTES, SMOOTH MUSCLE; PHENYLEPHRINE; RATS; RATS, WISTAR; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 36048936252     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Foley NR, Parfrey SP, Sarnak MJ. Cardiovascular disease in chronic renal failure: clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32: S112-9.
2. Pecoist-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation and atherosclerosis (MIA) syndrome: the heart of the matter. Nephrol Dial Transplant 2002; 17: 28-31.
3. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299-307.
4. Egashira K. Molecular mechanisms mediating inflammation in vascular disease: special reference to monacyte chemoatractant protein 1. Hypertension 2003; 41: 834-41.
5. Nicholas TE. A perfused tail artery preparation from the rat. J Pharm Pharmacol 1969; 21: 826-32.
6. Van Rossum J. Cumulative dose-response curves: technique for the making of dose-responses curves in isolated organs and the evaluation of drugs parameters. Arch Int Pharmacodyn Ther 1963; 143: 299-330.
7. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26.
8. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 2002; 80: 99-102.
9. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214-9.
10. Knight EL, Rimm EB, Pai JK, Rexrode KM, Cannuscio CC, Manson JE, Stampfer MJ, Curhan GC. Kidney dysfunction, inflammation and coronary events: a prospective study. J Am Soc Nephrol 2004; 15: 1897-903.
11. Roig E, Betriu A, Castaner A, Magrina J, Sanz G, Navarra-Lopez F. Disabling angina pectoris with normal coronary arteries in patients undergoing hemodialysis. Am J Med 1981; 71: 437-44.
12. Rostand RG, Kirk KA, Rutsky EA. Dialysis ischemic heart disease: insight from coronary anglography. Kidney Int 1984; 25: 653-9.
13. Chen L, Xin X, Eckhart AD, Yang N, Faber JE. Regulation of vascular smooth muscle growth by alpha 1-adrenoreceptor subtypes in vitro and in situ. J Biol Chem 1995; 270: 30980-8.
14. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbility, and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7: 728-36.
15. Cooper BA, Penne EL, Bartlett LH, Pollock CA. Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. Am J Kidney Dis 2004; 43: 61-6.
16. Giffen PS, Turton J, Andrews CM, Barrett P, Clarke CJ, Fung KW, Munday MR, Roman IF, Smyth R, Walshe K, York MJ. Markers of experimental acute inflammation in the Wistar Han rat with particular reference to haptoglobin and C-reactive protein. Arch Toxicol 2003; 77: 392-402.
17. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-16.
18. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Giovannini L, Norpoth M, Metelli MR, Cristofani R, Bertelli AA, Sbragia G, Tetta C, Palla R, Colombo R. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 2002; 91: 594-600.
19. Wang DL, Wung BS, Shyy YJ, Lin CF, Chao YJ, Usami S, Chien S. Mechanical strain induced monocyte chemoattractant protein-1 gene expression in endothelial cells: effects of mechanical strain on monocyte adhesion to endothelial cells. Circ Res 1995; 77: 294-302.
20. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439-41.
21. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle cells. Circulation 2003; 107: 1783-90.
22. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-6.
23. Tomita H, Egashira K, Kubo-Inoue M, Usui M, Koyanagi M, Shimokawa H, Takeya M, Yoshimura T, Takeshita A. Inhibition of nitric oxide synthesis induced inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol 1998; 18: 1456-64.
24. Khairallah PA, Davila D, Papanicolaou NM, Glende P, Meyer P. Effects of angiotensin infusion an catecholamine uptake and reactivity in blood vessel. Circ Res 1971; 28: 96-106.
25. Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, Polterauer S, Kapiotis S, Wolzt M. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004; 110: 3349-54.
26. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-91.
27. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
28. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
29. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 1713-24.
30. Bevers LM, Van Faassen EE, Vuong TD, Ni Z, Boer P, Koomans HA, Braam B, Vaziri ND, Joles JA. Low albumin levels increase endothelial NO production and decrease vascular NO sensitivity. Nephrol Dial Transplant 2006; 21: 3443-9